Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
A photographer finds thousands of dinosaur footprints near Italian Winter Olympic venue - 2Is new Harry Styles music on the way? Fans think so, after a cryptic website and posters pop up.
- 3The most effective method to Guarantee Simple Availability in Seniors' SUVs
- 4NASA's Apollo 8 moonshot saved 1968. Could Artemis 2 do the same in 2026?
- 5Civil rights leader Jesse Jackson hospitalized, family requests prayers
- 'Senseless violence' erupts at Christmas tree lighting; 4 injured
- Woman gives birth on roadside after hospital allegedly sent her home: Family
- Activists Took BMW and Mercedes to Court Over Gas Cars. It Didn’t Stick
- Far-right AfD invited back to Munich Security Conference in 2026
- Gartex Texprocess India to showcase innovations across textile ecosystem
- What causes RFK Jr.’s strained and shaky voice? A neurologist explains this little-known disorder
- Dental, Vision, and Hearing Inclusion in Senior Protection.
- EU Council president: Ukraine should receive binding guarantees
- SF Chinatown's historic Empress of China building being revived into cultural campus
